Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-612 and HER2-Targeted ADC in HR+, HER2-Low/Ultralow Metastatic Breast Cancer
NCT07757230Phase 2Recruiting
- Sponsor
- 3SBio
- Start
- Sep 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-612 in breast cancer, sponsored by 3SBio. Started Sep 2026; status: recruiting.
02
Drugs
SSGJ-612
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07757230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07757230.